We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
Consensus vs. actual, and revenue trend
Rating & price-target changes
Stored first · Google News · Yahoo Finance (English)
SYF Maintained by HSBC -- Price Target Raised to $97.00 - GuruFocus
SYF Maintained by HSBC -- Price Target Raised to $97.00 GuruFocus
HSBC Downgrades AstraZeneca(AZN.US) to Hold Rating, Cuts Target Price to $183.94 - 富途牛牛
HSBC Downgrades AstraZeneca(AZN.US) to Hold Rating, Cuts Target Price to $183.94 富途牛牛
HSBC Downgrade, Trial Setback Weigh on AstraZeneca - TradingPedia
HSBC Downgrade, Trial Setback Weigh on AstraZeneca TradingPedia
HSBC Downgrades AstraZeneca to Hold Rating, Cuts PT - marketscreener.com
HSBC Downgrades AstraZeneca to Hold Rating, Cuts PT marketscreener.com
HSBC Names New Head Of Trust, Fiduciary Services - Wealth Briefing
HSBC Names New Head Of Trust, Fiduciary Services Wealth Briefing
INTC Stock Has Surged 233% This Year — HSBC Sees Another 60% Upside As Foundry Business Becomes 'Too Good to Ignore' - Stocktwits
INTC Stock Has Surged 233% This Year — HSBC Sees Another 60% Upside As Foundry Business Becomes 'Too Good to Ignore' Stocktwits
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 04. | After market close (AMC) | — | — | — | $18.87B | — | Scheduled |
No research actions to show.
Price data
No holdings data to show.